<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-97896</identifier>
<setSpec>0365-6691</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Effectiveness of topical bevacizumab in bilateral primary lipid keratopathy</dc:title>
<dc:description xml:lang="en">Case report: A 75-year-old man with bilateral idiopathic lipid keratopathy underwent a penetrating keratoplasty in the left eye. One month later, there was deep corneal neovascularisation extending across the bed and the graft-host interface, with a whitish opacity surrounding the vessels. Topical bevacizumab (25mg/mL) was administered 4 times daily for 2 months with partial regression of corneal neovascularization. Discussion: Topical bevacizumab may be useful in preventing a recurrence of lipid deposition after penetrating keratoplasty in patients with bilateral primary lipid keratopathy, although its long-term efficacy needs to be assessed(AU)</dc:description>
<dc:creator>Montes-Mollón, M. A</dc:creator>
<dc:creator>Castro-Rebollo, M</dc:creator>
<dc:creator>Pérez-Rico, C</dc:creator>
<dc:creator>Teus, M. A</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Caso clínico: Varón de 75 años con queratopatía lipoidea bilateral primaria. Es intervenido de queratoplastia penetrante en ojo izquierdo. Al mes se observa neovascularización corneal profunda extendiéndose sobre el lecho y la interfase injerto-huésped, con opacidad blanquecina alrededor de los neovasos. Se inicia tratamiento con bevacizumab tópico (25mg/mL) 4 veces/día durante 2 meses, con regresión parcial de la neovascularización corneal.         Discusión: Bevacizumab tópico puede ser útil en la prevención de la recidiva de la queratopatía lipoidea tras queratoplastia penetrante en pacientes con queratopatía lipoidea bilateral primaria, aunque sería conveniente determinar su eficacia a largo plazo(AU)</dc:description>
<dc:source>Arch Soc Esp Oftalmol;86(11): 374-376, nov. 2011. ilus</dc:source>
<dc:identifier>ibc-97896</dc:identifier>
<dc:title xml:lang="es">Eficacia de bevacizumab tópico en queratopatía lipoidea bilateral primaria</dc:title>
<dc:subject>^d9582^s22057</dc:subject>
<dc:subject>^d30179^s22032</dc:subject>
<dc:subject>^d11621^s22045</dc:subject>
<dc:subject>^d30179^s22057</dc:subject>
<dc:subject>^d30179^s22016</dc:subject>
<dc:subject>^d21012</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d920^s22073</dc:subject>
<dc:subject>^d9062</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d30179^s29166</dc:subject>
<dc:type>article</dc:type>
<dc:date>201111</dc:date>
</metadata>
</record>
</ibecs-document>
